$KAPA News

Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate

Kairos Pharma signs deal for Celyn Therapeutics’ CL-273

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

Kairos Pharma Enters Into Binding Terms To Acquire CL-273 From Celyn Therapeutics For Undisclosed Sum; Transaction Is Expected To Be Value‑Accretive

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates From Celyn Therapeutics, Financial Terms Undisclosed

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

Kairos Pharma Provides Shareholder Update

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Kairos Pharma Presents Phase 2 Trial Of ENV-105 In Advanced Prostate Cancer As ESMO Meeting

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Kairos Pharma To Present Phase 2 Data On Apalutamide And Carotuximab In Advanced Prostate Cancer At ESMO 2025

Kairos Pharma reports positive data from Phase II prostate cancer treatment trial

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma shares are trading lower. The company announced efficacy data from its ongoing Phase 2 clinical trial of ENV105 in patients with metastatic castration-resistant prostate cancer.

Kairos Pharma shares are trading lower. The company announced efficacy data from its ongoing Phase 2 clinical trial of ENV105 in patients with metastatic castration-resistant prostate cancer.

Kairos Pharma Announces Efficacy Data From Ongoing Phase 2 Clinical Trial Of ENV105 In Patients With Metastatic Castration-Resistant Prostate Cancer

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer